ENSYSCE BIOSCIENCES, INC. Earnings Per Share (Basic)
ENSYSCE BIOSCIENCES, INC. (ENSC) reported Earnings Per Share (Basic) of -$0.20 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-13
- ENSYSCE BIOSCIENCES, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.20.
- ENSYSCE BIOSCIENCES, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.52.
- ENSYSCE BIOSCIENCES, INC. earnings per share, basic for the quarter ending 2025-12-31 was -$0.74.
- ENSYSCE BIOSCIENCES, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$1.29, a 229.00% decline year-over-year.
- ENSYSCE BIOSCIENCES, INC. earnings per share, basic for fiscal 2025 was -$3.98.
- ENSYSCE BIOSCIENCES, INC. earnings per share, basic for fiscal 2024 was -$11.45.
- ENSYSCE BIOSCIENCES, INC. earnings per share, basic for fiscal 2023 was -$70.40.
- ENSYSCE BIOSCIENCES, INC. earnings per share, basic for fiscal 2022 was -$139.42.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.20 10-Q · filed 2026-08-13 | -$0.62 10-Q · filed 2026-08-13 | -$1.13 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.91 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2026-03-31 | -$0.52 10-Q · filed 2026-05-15 | -$1.20 derived: net income ÷ weighted average shares · filed 2026-05-15 | -$2.24 derived: net income ÷ weighted average shares · filed 2026-05-15 | -$3.01 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-12-31 | -$0.74 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$1.97 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$2.80 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$3.98 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | -$1.29 10-Q · filed 2025-11-14 | -$2.15 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$3.42 10-Q · filed 2025-11-14 | -$5.68 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-06-30 | -$0.79 10-Q · filed 2026-08-13 | -$2.04 10-Q · filed 2026-08-13 | -$4.49 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$4.79 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-03-31 | -$1.39 10-Q · filed 2026-05-15 | -$4.18 derived: net income ÷ weighted average shares · filed 2026-05-15 | -$4.41 derived: net income ÷ weighted average shares · filed 2026-05-15 | -$7.02 derived: net income ÷ weighted average shares · filed 2026-05-15 | ||||
| 2024-12-31 | -$2.89 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$3.07 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$5.89 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$11.45 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $1.00 10-Q · filed 2025-11-14 | $0.07 10-Q · filed 2024-11-12 | -$2.09 derived: net income ÷ weighted average shares · filed 2025-11-14 | -$8.52 10-Q · filed 2025-11-14 | -$0.57 10-Q · filed 2024-11-12 | $7.54 derived: net income ÷ weighted average shares · filed 2025-11-14 | ||
| 2024-06-30 | -$3.35 10-Q · filed 2025-08-13 | -$0.22 10-Q · filed 2024-08-14 | -$9.98 10-Q · filed 2025-08-13 | -$0.67 10-Q · filed 2024-08-14 | $5.30 derived: net income ÷ weighted average shares · filed 2025-08-13 | $25.35 derived: net income ÷ weighted average shares · filed 2025-08-13 | ||
| 2024-03-31 | -$8.21 10-Q · filed 2025-05-13 | -$0.55 10-Q · filed 2024-05-13 | $2.43 derived: net income ÷ weighted average shares · filed 2025-05-13 | $11.80 derived: net income ÷ weighted average shares · filed 2025-05-13 | $495.84 derived: net income ÷ weighted average shares · filed 2025-05-13 | |||
| 2023-12-31 | $0.60 derived: net income ÷ weighted average shares · filed 2025-03-10 | $4.51 derived: net income ÷ weighted average shares · filed 2025-03-10 | $53.49 derived: net income ÷ weighted average shares · filed 2025-03-10 | -$70.40 10-K · filed 2025-03-10 | -$4.69 10-K · filed 2024-03-15 | |||
| 2023-09-30 | -$0.87 10-Q · filed 2024-11-12 | -$1.84 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$3.32 10-Q · filed 2024-11-12 | -$7.53 derived: net income ÷ weighted average shares · filed 2024-11-12 | ||||
| 2023-06-30 | -$0.98 10-Q · filed 2024-08-14 | -$2.66 10-Q · filed 2024-08-14 | -$8.22 derived: net income ÷ weighted average shares · filed 2024-08-14 | -$20.94 derived: net income ÷ weighted average shares · filed 2024-08-14 | ||||
| 2023-03-31 | -$2.08 10-Q · filed 2024-05-13 | -$11.37 derived: net income ÷ weighted average shares · filed 2024-05-13 | -$34.81 derived: net income ÷ weighted average shares · filed 2024-05-13 | -$61.73 derived: net income ÷ weighted average shares · filed 2024-05-13 | ||||
| 2022-12-31 | -$18.21 derived: net income ÷ weighted average shares · filed 2024-03-15 | -$66.48 derived: net income ÷ weighted average shares · filed 2024-03-15 | -$116.03 derived: net income ÷ weighted average shares · filed 2024-03-15 | -$139.42 10-K · filed 2024-03-15 | -$11.62 10-K · filed 2023-03-30 | |||
| 2022-09-30 | -$61.58 10-Q · filed 2023-11-09 | -$5.13 10-Q · filed 2022-11-14 | -$118.39 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$140.90 10-Q · filed 2023-11-09 | -$11.74 10-Q · filed 2022-11-14 | -$74.35 derived: net income ÷ weighted average shares · filed 2023-11-09 | ||
| 2022-06-30 | -$56.49 10-Q · filed 2023-08-11 | -$0.24 10-Q · filed 2022-08-11 | -$75.67 10-Q · filed 2023-08-11 | -$0.32 10-Q · filed 2022-08-11 | -$41.71 derived: net income ÷ weighted average shares · filed 2023-08-11 | -$56.06 derived: net income ÷ weighted average shares · filed 2023-08-11 | ||
| 2022-03-31 | -$14.66 10-Q · filed 2023-05-15 | -$0.06 10-Q · filed 2022-05-12 | -$18.76 derived: net income ÷ weighted average shares · filed 2023-05-15 | -$34.96 derived: net income ÷ weighted average shares · filed 2023-05-15 | -$6.58 derived: net income ÷ weighted average shares · filed 2023-05-15 | |||
| 2021-12-31 | -$8.89 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$23.03 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$4.70 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$29.64 10-K · filed 2023-03-30 | -$1.48 10-K · filed 2022-03-31 | |||
| 2021-09-30 | -$14.15 10-Q · filed 2022-11-14 | -$0.71 10-Q · filed 2021-11-15 | -$2.10 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$20.31 10-Q · filed 2022-11-14 | -$1.02 10-Q · filed 2021-11-15 | -$1.54 derived: net income ÷ weighted average shares · filed 2022-11-14 | ||
| 2021-06-30 | -$0.06 10-Q · filed 2022-08-11 | -$0.12 10-Q · filed 2022-08-11 | -$0.10 derived: net income ÷ weighted average shares · filed 2022-08-11 | -$0.00 derived: net income ÷ weighted average shares · filed 2022-08-11 | ||||
| 2021-03-31 | -$0.06 10-Q · filed 2022-05-12 | -$0.04 derived: net income ÷ weighted average shares · filed 2022-05-12 | $0.06 derived: net income ÷ weighted average shares · filed 2022-05-12 | |||||
| 2020-12-31 | $0.01 derived: net income ÷ weighted average shares · filed 2022-03-31 | $0.11 derived: net income ÷ weighted average shares · filed 2022-03-31 | $0.00 10-K · filed 2022-03-31 | |||||
| 2020-09-30 | $0.10 10-Q · filed 2021-11-15 | -$0.01 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |